AIM: Stereotactic radiosurgery (SRS) is often used in the treatment of brain metastatic melanoma. Little data exist regarding outcomes of repeat course of SRS in this population. We aimed to identify treatment outcomes and toxicities in melanoma patients treated with repeat SRS after upfront SRS. PATIENTS & METHODS: We reviewed ten consecutive patients treated with repeat SRS following upfront SRS alone for brain metastatic melanoma. RESULTS: The median overall survival from initial treatment was 17.5 months. The median overall survival from repeat SRS was 6.7 months with a 6-month local control rate of 80%. The majority of patients progressed systemically before death. Four patients reported six adverse events, all grade 1. CONCLUSION: Prospective study regarding the safety and efficacy of repeat courses of SRS in patients with brain-metastatic melanoma, especially in combination with novel immunotherapies, is warranted.
AIM: Stereotactic radiosurgery (SRS) is often used in the treatment of brain metastatic melanoma. Little data exist regarding outcomes of repeat course of SRS in this population. We aimed to identify treatment outcomes and toxicities in melanoma patients treated with repeat SRS after upfront SRS. PATIENTS & METHODS: We reviewed ten consecutive patients treated with repeat SRS following upfront SRS alone for brain metastatic melanoma. RESULTS: The median overall survival from initial treatment was 17.5 months. The median overall survival from repeat SRS was 6.7 months with a 6-month local control rate of 80%. The majority of patients progressed systemically before death. Four patients reported six adverse events, all grade 1. CONCLUSION: Prospective study regarding the safety and efficacy of repeat courses of SRS in patients with brain-metastatic melanoma, especially in combination with novel immunotherapies, is warranted.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: James E Bates; Paul Youn; Kenneth Y Usuki; Kevin A Walter; Christine F Huggins; Paul Okunieff; Michael T Milano Journal: J Neurooncol Date: 2015-09-09 Impact factor: 4.130
Authors: Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud Journal: Lancet Date: 2014-07-15 Impact factor: 79.321
Authors: Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Dirk Rades; Lena Sehmisch; Stefan Huttenlocher; Oliver Blank; Dagmar Hornung; Patrick Terheyden; Jan Gliemroth; Steven E Schild Journal: Anticancer Res Date: 2014-09 Impact factor: 2.480
Authors: Robert H Press; Roshan S Prabhu; Dana C Nickleach; Yuan Liu; Hui-Kuo G Shu; Shravan Kandula; Kirtesh R Patel; Walter J Curran; Ian Crocker Journal: Cancer Date: 2015-08-04 Impact factor: 6.860
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Scott C Lester; Glen B Taksler; J Griff Kuremsky; John T Lucas; Diandra N Ayala-Peacock; David M Randolph; J Daniel Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Cancer Date: 2013-10-21 Impact factor: 6.921
Authors: Isabela Peña Pino; Jun Ma; Yusuke S Hori; Elena Fomchenko; Kathryn Dusenbery; Margaret Reynolds; Christopher Wilke; Jianling Yuan; Ethan Srinivasan; Matthew Grabowski; Peter Fecci; Evidio Domingo-Musibay; Naomi Fujioka; Gene H Barnett; Veronica Chang; Alireza M Mohammadi; Clark C Chen Journal: J Neurooncol Date: 2022-01-10 Impact factor: 4.130